# Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

> **NCT02372955** · PHASE4 · UNKNOWN · sponsor: **Gulf Regional Research & Educational Services, LLC** · enrollment: 21 (estimated)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** glimpiride

## Key facts

- **NCT ID:** NCT02372955
- **Lead sponsor:** Gulf Regional Research & Educational Services, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2016-02
- **Final completion:** 2016-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2015-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372955, "Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02372955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*